Pipeline

From science originally developed at Weill Cornell Medicine, we're pioneering a pipeline of precision oncology therapeutics that target ICAM-1 in indications with significant unmet medical needs.

Preclinical

Phase 1

Pivotal

ICAM-1 + Tracking

Indication: Thyroid

ICAM-1 + Tracking

Indication: Thyroid

Preclinical

Phase 1

Pivotal

AIC100

AIC100 has received RMAT, Orphan Drug, and Fast Track Designations

ICAM-1 + Tracking

Indication: Non-Small Cell Lung Cancer

ICAM-1 + Tracking

Indication: Non-Small Cell Lung Cancer

Preclinical

Phase 1

Pivotal

Non-small cell lung cancer IND filing targeted in 2025